Effect of neoadjuvant epirubicin and total androgen blockade on complete pathological response in patients with clinical stage T3/T4 prostate cancer

• Published in: European journal of surgical oncology Vol. 34; no. 2; pp. 216 - 221
• Main Authors: Francini, G, Paolelli, L, Francini, E, Pascucci, A, Manganelli, A, Salvestrini, F, Petrioli, R
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01-02-2008
• Subjects: Aged; Androgen Antagonists - administration & dosage; Antineoplastic Agents, Hormonal - administration & dosage; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Epirubicin - administration & dosage; Follow-Up Studies; Hematology, Oncology and Palliative Medicine; Hormonal therapy; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Neoadjuvant treatment; Neoplasm Staging; Postoperative Care - methods; Preoperative Care - methods; Prostate cancer; Prostate-Specific Antigen - blood; Prostatectomy - methods; Prostatic Neoplasms - mortality; Prostatic Neoplasms - pathology; Prostatic Neoplasms - therapy; Radiotherapy, Adjuvant; Risk Assessment; Surgery; Survival Rate; Treatment Outcome; Epirubicin; Prostate cancer; Neoadjuvant treatment; Hormonal therapy
• ISSN: 0748-7983; 1532-2157
• DOI: 10.1016/j.ejso.2007.03.016

Abstract Aims Most patients with stage T3–T4 prostate cancer experience disease relapse despite radiation and/or hormonal therapy, and their management remains controversial. We investigated the feasibility of, and the pathological response induced by neoadjuvant chemo-hormonal treatment in men with clinical stage T3/T4. Methods Fifteen patients underwent neoadjuvant therapy consisting of weekly intravenous infusions of epirubicin 30 mg/m2 and total androgen blockade (TAB) for three months before undergoing radical prostatectomy, after which all received locoregional conformal radiotherapy (66 Gy) and then continued with TAB and three additional months of epirubicin. Results After neoadjuvant therapy, PSA levels decreased in all 15 patients and became undetectable in two. None of the patients achieved a complete pathological response, but a 35–75% reduction in tumour size was observed in all cases, and all the patients were able to undergo successful prostatectomy. Pathological assessments of the surgical specimens revealed negative margins in 13 patients. After a median follow-up of 34 months (range 11–62), 14 patients (93%) are still clinically and biochemically disease free. No grade 3 or 4 complications occurred. Conclusion This study suggests that neoadjuvant treatment with epirubicin and TAB is feasible and well tolerated in patients with clinical stage T3–T4 prostate cancer.